A growing tumour is an evolving system: during tumour development, cancer cells randomly acquire mutations that may provide them with a beneficial phenotype. However, such alterations can also give rise to neoantigens – novel cancer-specific peptides presented on the cell surface that trigger host immune responses. Successfully navigating interactions with the microenvironment and overcoming...
Immunotherapeutic approaches that exploit and manipulate cellular immune responses have increased our ability to treat various malignant diseases. However, these approaches still have their limitations and tend to fail in numerous patients, requiring a more mechanistic and quantitative understanding about the complex, intermingled dynamics of cell migration, differentiation and turnover that...
The Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs) are slowly developing haematological malignancies characterised by an overproduction of blood cells. Chronic inflammation is associated with the diseases and suggested to play an important role in disease initiation and progression as well as being a consequence of the diseases.
In the DALIAH trial, treatment-naïve MPN...
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of hematological malignancies arising from lymphoid cells. In relapsed or refractory cases, chimeric antigen receptor (CAR) T-cell therapy offers a potentially curative treatment by engineering patient-derived T-cells to target tumor-associated antigens. Despite promising outcomes, treatment response remains variable across patients....
The mathematical models of cancer onset and progression increasingly reflect the emerging view of tumors and the cancer-immune system as complex ecosystems. In combination with empirical evidence and statistical approaches, mathematical models of ecological and eco-evolutionary dynamics of cancer have gained increased importance for both theorists and experimentalists.
This minisymposium...
